Last checked at 25 Jun 2010 15:47
Directors' Shareholdings
25 June 2010
Deltex Medical Group plc ("Deltex Medical" or the "Company"), the global leader in oesophageal Doppler monitoring ("ODM"), announces that it has today issued a total of 206,785 new ordinary shares of 1p each in the Company ("New Ordinary Shares") to four non-executive directors and one executive director of the Company at a price of 11.75 pence per share.
The four non-executive directors named below have elected to take shares in lieu of a cash payment as remuneration for their services to the Company for the period 1 April 2010 to 30 June 2010.
The one executive director, Paul Mitchell, named below has elected to take shares in lieu of a cash payment corresponding to the salary increase awarded by the Company's remuneration committee in respect of the period 1 April 2010 to 30 June 2010.
In addition to the above, the Company also announces that it has today issued a total of 182,609 New Ordinary Shares to a certain adviser of the Company at a price of 11.50 pence per share.
Accordingly, application has been made for these shares to be admitted to trading on AIM. The shares rank pari passu with the existing issued shares of the Company and dealings are expected to commence on Thursday 1 July 2010. Following the issue of these new shares the Company has a total of 127,606,565 ordinary shares of 1p each in issue.
Following this issue, the directors' beneficial interests are as follows:
| Name of director | Number of New Ordinary Shares issued in lieu of fees/salary
| Holding of shares following issue of New Ordinary Shares
| % of enlarged issued share capital |
| Nigel Keen | 70,921 | 5,542,050 | 4.34 |
| Dr Edwin Snape (1) | 51,064 | 4,326,661 | 3.39 |
| Sir Duncan Nichol | 30,638 | 562,469 | 0.44 |
| Julian Cazalet | 40,584 | 3,402,882 | 2.67 |
| Paul Mitchell | 13,578 | 195,117 | 0.15 |
(1) Includes shares held as a principal of Nexus Medical Partners II, L.P.
For further information, please contact:-
Deltex Medical Group plc 01243 774 837Nigel Keen, Chairman Ewan Phillips, Chief Executive Paul Mitchell, Finance Director
Nominated Adviser and Broker 020 7614 5917
Arden Partners plc
Christopher Hardie
Matthew Armitt